SEC Form 4 · accession 0001140361-17-047168
NEVRO CORP · NVRO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Michael F Demane
Director
Period of report
Dec 21, 2017
Accepted (ET)
Dec 22, 2017 · 3:19 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001444380
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Dec 21, 2017 | M | 41,572 | $3.60 | A | 468,885 | D | |
| Common StockF2 | holding | — | — | — | 42,554 | I | See footnote | |
| Common StockF3 | holding | — | — | — | 50,000 | I | See footnote |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F4 | $3.60 | Dec 21, 2017 | M | 41,572 | D | — | May 14, 2023 | Common Stock | 41,572 | 0 | D |
Explanation of responses
- F1Includes 1,518 restricted stock units.
- F2Shares held by Catherine Q. DeMane Trustee, Michael F. DeMane 2012 Irrevocable Trust U/A/D July 26, 2012.
- F3Shares held by Michael DeMane Trustee, Michael F. DeMane 2016 Retailed Annuity Trust U/A/D May 22, 2017.
- F4100% of the shares subject to the option are fully vested and exercisable.